Long-term Prognostic Importance of High Levels of SST2 in Patient with AMI: a Meta-analysis

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2024 Feb 7

PMID 38322566

Authors

Haigang Ji

Ling Yuan

Wenbo Jiang

Jing Chen

Affiliations

Soon will be listed here.

Abstract

Objective: This meta-study aimed to assess the connection between soluble suppression of tumorigenicity 2 (sST2) and extended clinical outcomes in individuals diagnosed with acute myocardial infarction (AMI).

Methods: We systematically collected pertinent literature from PubMed, Embase and Web of Science. The primary effect measures employed in this research were the hazard ratio and 95% confidence intervals. The quality and publication bias of included studies were evaluated. Subgroup analysis was conducted to explore the diversity in study outcomes.

Results: This comprehensive meta-analysis ultimately encompassed thirteen studies, involving a total of 11,571 patients. Elevated levels of sST2 were identified as an adverse prognostic indicator, demonstrating a substantial association not only with overall mortality (combined HR 2.4, 95% CI 1.6-3.5, P < 0.01) but also with major adverse cardiovascular events (MACEs) (HR 2.5, 95% CI 1.5-4.2, P < 0.01). Subgroup analyses revealed that increased sST2 levels were linked to higher rates of all-cause mortality and MACEs in patients with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and other unselected subcategories of AMI.

Conclusion: Increased sST2 could predict the long-term prognosis in patients suffering from AMI.

References

Zhang Y, Zhang L, Chen Z . Effect of combining sST2/HDL-C ratio with risk factors of coronary heart disease on the detection of angina pectoris in Chinese: a retrospective observational study. Cardiovasc Diagn Ther. 2023; 13(2):345-354. PMC: 10423738. DOI: 10.21037/cdt-22-520. View

Zhao H, Cheng J . Associations between Ambient Temperature and Acute Myocardial Infarction. Open Med (Wars). 2019; 14:14-21. PMC: 6310921. DOI: 10.1515/med-2019-0003. View

Plakht Y, Gilutz H, Shiyovich A . Temporal trends in acute myocardial infarction: What about survival of hospital survivors? Disparities between STEMI & NSTEMI remain. Soroka acute myocardial infarction II (SAMI-II) project. Int J Cardiol. 2015; 203:1073-81. DOI: 10.1016/j.ijcard.2015.11.072. View

Heydari B, Abdullah S, Shah R, Francis S, Feng J, McConnell J . Omega-3 Fatty Acids Effect on Post-Myocardial Infarction ST2 Levels for Heart Failure and Myocardial Fibrosis. J Am Coll Cardiol. 2018; 72(8):953-955. DOI: 10.1016/j.jacc.2018.06.018. View

Desnos C, Ederhy S, Belnou P, Lapidus N, Lefevre G, Voiriot G . Prognostic performance of GRACE and TIMI risk scores in critically ill patients with sepsis and a concomitant myocardial infarction. Arch Cardiovasc Dis. 2022; 115(6-7):359-368. DOI: 10.1016/j.acvd.2022.03.007. View

Sakamoto J, Liu N, Koh Z, Fung N, Heldeweg M, Ng J . Comparing HEART, TIMI, and GRACE scores for prediction of 30-day major adverse cardiac events in high acuity chest pain patients in the emergency department. Int J Cardiol. 2016; 221:759-64. DOI: 10.1016/j.ijcard.2016.07.147. View

Jenkins W, Roger V, Jaffe A, Weston S, AbouEzzeddine O, Jiang R . Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med. 2017; 130(9):1112.e9-1112.e15. PMC: 5572469. DOI: 10.1016/j.amjmed.2017.02.034. View

Sciatti E, Merlo A, Scangiuzzi C, Limonta R, Gori M, DElia E . Prognostic Value of sST2 in Heart Failure. J Clin Med. 2023; 12(12). PMC: 10299183. DOI: 10.3390/jcm12123970. View

Pedrinelli R, Ballo P, Fiorentini C, Denti S, Galderisi M, Ganau A . Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown). 2012; 13(3):194-202. DOI: 10.2459/JCM.0b013e3283511ee2. View

10.

Altara R, Ghali R, Mallat Z, Cataliotti A, Booz G, Zouein F . Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc Res. 2018; 114(12):1578-1594. DOI: 10.1093/cvr/cvy166. View

11.

Zhang Q, Hu M, Ma S . Association of Soluble Suppression of Tumorigenicity with No-Reflow Phenomenon and Long-Term Prognosis in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome after Percutaneous Coronary Intervention. J Atheroscler Thromb. 2021; 28(12):1289-1297. PMC: 8629709. DOI: 10.5551/jat.59832. View

12.

Weir R, Miller A, Murphy G, Clements S, Steedman T, Connell J . Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55(3):243-50. DOI: 10.1016/j.jacc.2009.08.047. View

13.

Yu J, Oh P, Kim M, Moon J, Park Y, Lee K . Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS One. 2017; 12(8):e0182829. PMC: 5552027. DOI: 10.1371/journal.pone.0182829. View

14.

Fu A, Hung K, Yuen M, Zhou X, Mak D, Chan I . IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016; 113(19):E2705-13. PMC: 4868478. DOI: 10.1073/pnas.1604032113. View

15.

Hjort M, Eggers K, Lindhagen L, Baron T, Erlinge D, Jernberg T . Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clin Biochem. 2021; 98:17-23. DOI: 10.1016/j.clinbiochem.2021.09.001. View

16.

Fang C, Yin Y, Jiang S, Zhang S, Wang J, Wang Y . Increased Vulnerability and Distinct Layered Phenotype at Culprit and Nonculprit Lesions in STEMI Versus NSTEMI. JACC Cardiovasc Imaging. 2021; 15(4):672-681. DOI: 10.1016/j.jcmg.2021.07.022. View

17.

Pascual-Figal D, Perez-Martinez M, Asensio-Lopez M, Sanchez-Mas J, Garcia-Garcia M, Martinez C . Pulmonary Production of Soluble ST2 in Heart Failure. Circ Heart Fail. 2018; 11(12):e005488. DOI: 10.1161/CIRCHEARTFAILURE.118.005488. View

18.

Pascual-Figal D, Lax A, Perez-Martinez M, Asensio-Lopez M, Sanchez-Mas J . Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2015; 54(1):29-35. DOI: 10.1515/cclm-2015-0074. View

19.

Dhillon O, Narayan H, Khan S, Kelly D, Quinn P, Squire I . Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?. Int J Cardiol. 2012; 167(5):2182-8. DOI: 10.1016/j.ijcard.2012.05.073. View

20.

Saikumar Jayalatha A, Hesse L, Ketelaar M, Koppelman G, Nawijn M . The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacol Ther. 2021; 225:107847. DOI: 10.1016/j.pharmthera.2021.107847. View